Copyright
©The Author(s) 2020.
World J Hepatol. Sep 27, 2020; 12(9): 619-627
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.619
Published online Sep 27, 2020. doi: 10.4254/wjh.v12.i9.619
Table 1 Charlson Co-morbidity index
| Co-morbid condition | cCCI weights | uCCI weights |
| Myocardial infarction | 1 | 0 |
| Congestive heart failure | 1 | 2 |
| Peripheral vascular disease | 1 | 0 |
| Cerebrovascular disease | 1 | 0 |
| Dementia | 1 | 2 |
| Chronic obstructive pulmonary disease | 1 | 1 |
| Connective tissue disorder | 1 | 1 |
| Peptic ulcer disease | 1 | 0 |
| Mild liver disease | 1 | 2 |
| Diabetes without complication | 1 | 0 |
| Diabetes with complication | 2 | 1 |
| Hemiplegia or paraplegia | 2 | 2 |
| Chronic kidney disease stage III | 2 | 1 |
| Any malignancy without metastasis | 2 | 2 |
| Leukemia | 2 | |
| Lymphoma | 2 | |
| Moderate or severe liver disease | 3 | 4 |
| Metastatic tumor | 6 | 6 |
| AIDS | 6 | 4 |
| Maximum score | 33 | 24 |
Table 2 Demographic and baseline characteristics of the study population
| Variable | Study population (n = 130) |
| Age, yr, median (IQR) | 62 (48, 73) |
| Females | 59 (45.4) |
| Body mass index, kg/m2, median (IQR) | 28.7 (26, 36) |
| Smoking | 38 (29.2) |
| Alcohol | 30 (23.1) |
| Diarrhea | 34 (26.2) |
| Nausea | 32 (24.6) |
| Abdominal pain | 21 (16.2) |
| Anorexia | 34 (26.2) |
| Other gastro-intestinal symptoms1 | 37 (28.5) |
| X-ray findings2 | 87 (66.9) |
| Hypertension | 69 (53.1) |
| Admitted to ICU | 58 (44.6) |
| On ventilator | 43 (33.1) |
| Age-adjusted Charlson Index, median (IQR) | 3.5 (1, 6) |
| On medications with gastro-intestinal side-effects | 46 (35.4) |
| Death | 28 (21.5) |
| Lactic Acid, mean (SD), n = 97 | 1.7 (1.4) |
| Lactic acid dehydrogenase, mean (SD), n = 92 | 424 (182.6) |
| D-dimer, median (IQR), n = 105 | 1.7 (0.9, 3.7) |
| Alanine aminotransferase, IU/L, median (IQR) | 29 (16, 53) |
| Aspartate aminotransferase, IU/L, median (IQR) | 39 (23, 68) |
| Alkaline phosphatase, IU/L, median (IQR) | 77 (60, 115) |
| Total bilirubin, mean (SD) | 0.4 (0.3) |
| Direct bilirubin, mean (SD), n = 92 | 0.2 (0.1) |
| Albumin, g/dL, mean (SD) | 3.2 (0.8) |
| Prothrombin time, seconds, mean (SD), n = 81 | 16.9 (8.1) |
Table 3 Characteristics of those with and without transaminitis
| Transaminitis (n = 73) | No transaminitis (n = 57) | P value | |
| Age, yr, median (IQR) | 63 (48, 72) | 62 (48, 76) | 0.9 |
| Females | 31 (42.5) | 28 (49.1) | 0.4 |
| Body mass index, kg/m2, median (IQR) | 30.2 (26.5, 36.8) | 27.3 (24.5, 33.2) | 0.04 |
| Smoking | 19 (26) | 19 (33.3) | 0.4 |
| Alcohol | 20 (27.4) | 10 (17.5) | 0.2 |
| Diarrhea | 24 (32.9) | 10 (17.5) | 0.05 |
| Nausea | 18 (24.7) | 14 (24.6) | 1.0 |
| Abdominal pain | 11 (15.1) | 10 (17.5) | 0.7 |
| Anorexia | 19 (26) | 15 (26.3) | 1.0 |
| Other gastro-intestinal symptoms1 | 19 (26) | 18 (31.6) | 0.5 |
| X-ray findings2 | 55 (75.3) | 32 (56.1) | 0.02 |
| Hypertension | 38 (52.1) | 31 (54.4) | 0.8 |
| Age-adjusted Charlson Index, median (IQR) | 3 (1, 6) | 4 (1, 6) | 0.7 |
| On ventilator | 31 (42.5) | 12 (21.1) | 0.01 |
| Admitted to intensive care unit | 39 (53.4) | 19 (33.3) | 0.02 |
| On medications with GI side-effects | 26 (35.6) | 20 (35.1) | 1.0 |
| Alanine aminotransferase, IU/L, median (IQR) | 48 (34, 84) | 15 (10, 20) | < 0.001 |
| Aspartate aminotransferase, IU/L, median (IQR) | 66 (42, 100) | 20 (14, 26) | < 0.001 |
| Alkaline phosphatase, IU/L, median (IQR) | 97 (66, 124) | 70 (56, 92) | < 0.001 |
| Total bilirubin, mean (SD) | 0.6 (0.3) | 0.4 (0.2) | < 0.001 |
| Albumin, g/dL, mean (SD) | 3.0 (0.8) | 3.4 (0.7) | 0.01 |
Table 4 Multivariable logistic model for death in patients with and without transaminitis
| Variable | Model 1 | Model 2 | Model 3 | |||
| OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | |
| Transaminitis | 2.9 (1.1-7.4) | 0.03 | 3.1 (1.2-8.0) | 0.02 | 3.4 (1.2-10.1) | 0.03 |
| Gender, reference females | - | 0.5 (0.2-1.2) | 0.5 (0.2-1.4) | |||
| AACI above median score of 3.5 | - | - | 12.9 (3.5-48.4) | |||
| Admission to intensive care unit | - | - | 3.6 (1.2-10.4) | |||
- Citation: Suresh Kumar VC, Harne PS, Mukherjee S, Gupta K, Masood U, Sharma AV, Lamichhane J, Dhamoon AS, Sapkota B. Transaminitis is an indicator of mortality in patients with COVID-19: A retrospective cohort study. World J Hepatol 2020; 12(9): 619-627
- URL: https://www.wjgnet.com/1948-5182/full/v12/i9/619.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i9.619
